Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
By: PR Newswire Association LLC. - 25 Jan 2023Back to overview list

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..

Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form-2/?id=35875&from=4

CLASS PERIOD: This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022,  inclusive.

ALLEGATIONS: According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from  the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.

DEADLINE: February 3, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form-2/?id=35875&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 3, 2023. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm

15 West 38th Street, 12th floor

New York, NY, 10018

Email: dg@securitiesclasslaw.com

Phone: (646) 453-8903

Cision View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-spectrum-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-3-2023--nasdaq-sppi-301729962.html

SOURCE The Gross Law Firm

Related companies:Spectrum Pharmaceuticals
Copyright 2023 PR Newswire Association LLC. Back to overview list
to the top ↑
{literal} {/literal}